| Literature DB >> 26985310 |
David L Wilson1, Isabel Meininger2, Zack Strater1, Stephanie Steiner1, Frederick Tomlin1, Julia Wu1, Haya Jamali1, Daniel Krappmann2, Marion G Götz1.
Abstract
This research explores the first design and synthesis of macrocyclic peptide aldehydes as potent inhibitors of the 20S proteasome. Two novel macrocyclic peptide aldehydes based on the ring-size of the macrocyclic natural product TMC-95 were prepared and evaluated as inhibitors of the 20S proteasome. Both compounds inhibited in the low nanomolar range and proved to be selective for the proteasome over other serine and cysteine proteases, particularly when compared to linear analogues with similar amino acid sequences. In HeLa cells, both macrocycles efficiently inhibited activation of nuclear factor-κB (NF-κB) transcription factor by blocking proteasomal degradation of the inhibitor protein IκBα after cytokine stimulation. Due to their covalent mechanism of binding these compounds represent a 1000-fold increase in inhibitory potency over previously reported noncovalently binding TMC-95 analogues. Molecular modeling of the macrocyclic peptides confirms the preference of the large S3 pocket for large, hydrophobic residues and the ability to exploit this to improve selectivity of proteasome inhibitors.Entities:
Keywords: Proteasome; aldehyde; inhibitor; macrocycle; multiple myeloma
Year: 2016 PMID: 26985310 PMCID: PMC4789680 DOI: 10.1021/acsmedchemlett.5b00401
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345